Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Prostate cancer is one of the most common cancers worldwide. We present a unique case of metastatic prostate cancer manifesting initially with a psoas muscle mass causing abdominal and hip pain. Computed tomography (CT) imaging revealed a large mass within the left psoas muscle with prominent pelvic and retroperitoneal lymphadenopathy, initially concerning for rhabdomyosarcoma. However, a biopsy of the psoas mass confirmed metastatic prostate adenocarcinoma. Interestingly, a nuclear whole-body bone scan and spinal MRI were negative for bone involvement or other metastases. The patient was treated with anti-androgen therapy along with abiraterone and docetaxel and had a positive serologic and radiologic response. He was also offered radiation as per the phase III Prostate Cancer Consortium in Europe-1 (PEACE-1) trial. This case underscores the importance of recognizing atypical metastatic sites, such as skeletal muscle, in prostate cancer, as they can complicate initial diagnosis and delay management. Understanding the mechanisms of rare metastatic patterns and the diagnostic approaches required is crucial for improving outcomes in prostate cancer patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207938PMC
http://dx.doi.org/10.7759/cureus.85127DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
psoas muscle
12
bone involvement
8
metastatic prostate
8
prostate
7
cancer
6
rare presentation
4
presentation prostate
4
psoas
4
cancer psoas
4

Similar Publications

Background: Rhabdomyosarcoma (RMS) typically responds well to a combination of treatments with favorable prognosis in children 1 to 9 years old. However, infants may fare worse due to receiving less aggressive local therapy for concerns about long-term effects of surgery/radiation. This study investigates the clinical characteristics, treatment approach, and survival outcomes of RMS in children under 2.

View Article and Find Full Text PDF

MicroRNAs (miRNAs) are critical regulators of gene expression in cancer biology, yet their spatial dynamics within tumor microenvironments (TMEs) remain underexplored due to technical limitations in current spatial transcriptomics (ST) technologies. To address this gap, we present STmiR, a novel XGBoost-based framework for spatially resolved miRNA activity prediction. STmiR integrates bulk RNA-seq data (TCGA and CCLE) with spatial transcriptomics profiles to model nonlinear miRNA-mRNA interactions, achieving high predictive accuracy (Spearman's ρ > 0.

View Article and Find Full Text PDF

Human Kallikrein 2 (KLK2) is a prostate cancer tissue specific protein that is regulated by androgen receptor (AR) signaling. KLK2 was not previously recognized as a therapeutic target as it is secreted. It has now been demonstrated that KLK2 is expressed on the cell surface and targetable by various methodologies.

View Article and Find Full Text PDF

This study focuses on designing and developing a novel three-dimensional porphyrinic covalent organic framework (3D-Por-COF) to enhance anticancer sono-photodynamic therapy (SPDT). Leveraging the unique structural advantages of 3D COFs, this work addresses the limitations of traditional 2D-Por-COFs, particularly regarding reactive oxygen species (ROS) production and therapeutic efficacy. The newly developed 3D-Por-COF demonstrated significantly higher ROS generation under combined sonodynamic and photodynamic conditions, leading to an improved therapeutic effect against prostate cancer cells.

View Article and Find Full Text PDF

Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.

Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.

Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.

View Article and Find Full Text PDF